爱通立疾病知识培训——脑卒中培训(瞬间溶栓-生机再现).ppt

爱通立疾病知识培训——脑卒中培训(瞬间溶栓-生机再现).ppt

  1. 1、本文档共65页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
* 由此我们看出,ECASS研究同样证实:患者在接受治疗后,神经功能改善明显,因此我们可以得出这样的结论:急性缺血性脑卒中发生6小时内应用爱通立溶栓治疗对改善患者的神经功能依然有利,溶栓治疗时间窗可以视情况拓宽到6小时。 * Both the international scientific society and the European health authorities would like to know whether thrombolysis initiated between 3 and 4.5 hours after stroke onset is effective and safe as suggested by a pooled analysis of the ATLANTIS, ECASS and NINDS rt-PA trials. Therefore ECASS III aims to evaluate efficacy and safety in the 3–4.5-hour time window.20 ECASS III is be a double-blind, randomised, placebo-controlled trial in the 3–4.5-hour time window with approximately 400 patients per study arm and the ECASS II dose of rt-PA.40–41 * Both the international scientific society and the European health authorities would like to know whether thrombolysis initiated between 3 and 4.5 hours after stroke onset is effective and safe as suggested by a pooled analysis of the ATLANTIS, ECASS and NINDS rt-PA trials. Therefore ECASS III aims to evaluate efficacy and safety in the 3–4.5-hour time window.20 ECASS III is be a double-blind, randomised, placebo-controlled trial in the 3–4.5-hour time window with approximately 400 patients per study arm and the ECASS II dose of rt-PA.40–41 * * A post-hoc adjusted ITT analysis (logistic regression) for the primary endpoint was undertaken for sensitivity purposes. This was conducted by including all baseline variables in the model and retaining those that were significant at P0.1. Thus treatment, baseline NIHSS, stroke onset to treatment time, smoking history and prior hypertension were retained. Treatment with rt-PA in this final prognostic model remains significant (P=0.037) with an OR of 1.42 and a 95% CI of (1.02 - 1.98). Age, prior stroke and diabetes were not prognostic at p0.1 and their inclusion inevitably introduces more variability; nevertheless, after also forcing these variables into the prognostic model, treatment with rt-PA remains significant (P=0.0495) with an OR of 1.40 and a 95% CI of (1.00 - 1

文档评论(0)

喵咪147 + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档